August 18, 2014 / 12:57 PM / 3 years ago

BUZZ-Tekmira Pharmaceuticals Corp: Up on research action

** Drug developer’s U.S.-listed shares up 8.7 pct at $19.61 premarket

** Leerink Swann LLC starts covering stock with “outperform” rating and $25 price target

** “We believe Tekmira’s (lipid-nanoparticle nucleic acid) platform represents a best-in-class technology that has been clinically validated,” analyst Michael Schmidt writes in note

** Of 3 other analysts covering stock, 1 has “strong buy” rating and 2 have “buy”

** Median price target on stock is $26.25, down from $28.75 two months ago

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below